Sonnet Biotherapeutics Holdings Inc Cash Flow Conversion Efficiency
Sonnet Biotherapeutics Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Sonnet Biotherapeutics Holdings Inc (SONN) has a cash flow conversion efficiency ratio of 0.577x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($-3.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sonnet Biotherapeutics Holdings Inc (2009–2025)
Cash flow conversion efficiency of Sonnet Biotherapeutics Holdings Inc from 2009 to 2025. This chart illustrates how Sonnet Biotherapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sonnet Biotherapeutics Holdings Inc (SONN) stock price for real-time trading data and today's change.
Sonnet Biotherapeutics Holdings Inc Cash Flow Conversion Ratio Explained
Sonnet Biotherapeutics Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sonnet Biotherapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonnet Biotherapeutics Holdings Inc ranked by their cash flow conversion efficiency. Also see Sonnet Biotherapeutics Holdings Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inepar S.A. Indústria e Construções
SA:INEP3
|
0.014x |
|
Nico Resources Ltd
AU:NC1
|
-0.004x |
|
RLF Agtech Ltd
AU:RLF
|
-0.192x |
|
Richy Place 2002 Public Company Limited
BK:RICHY
|
0.038x |
|
Nagarjuna Fertilizers and Chemicals Limited
NSE:NAGAFERT
|
0.074x |
|
Silver Range Resources Ltd
V:SNG
|
-0.017x |
|
Holista Colltech Ltd
AU:HCT
|
-0.382x |
|
Aakash Exploration Services Limited
NSE:AAKASH
|
0.010x |
Annual Cash Flow Conversion Efficiency for Sonnet Biotherapeutics Holdings Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Sonnet Biotherapeutics Holdings Inc from 2009 to 2025. Review SONN FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $10.79 Million | $-12.83 Million | -1.189x | -106.71% |
| 2024-09-30 | $-485.74K | $-8.61 Million | 17.721x | -81.24% |
| 2023-09-30 | $-225.98K | $-21.34 Million | 94.441x | +765.96% |
| 2022-09-30 | $-2.54 Million | $-27.69 Million | 10.906x | +1176.46% |
| 2021-09-30 | $22.26 Million | $-22.55 Million | -1.013x | +80.41% |
| 2020-09-30 | $3.02 Million | $-15.61 Million | -5.171x | -761.04% |
| 2019-09-30 | $-2.85 Million | $-2.23 Million | 0.782x | +1340.48% |
| 2017-09-30 | $11.49 Million | $-724.43K | -0.063x | -72.91% |
| 2016-09-30 | $13.96 Million | $-509.16K | -0.036x | +85.21% |
| 2015-12-31 | $21.76 Million | $-5.36 Million | -0.247x | +31.18% |
| 2015-09-30 | $14.97 Million | $-5.36 Million | -0.358x | -48.88% |
| 2013-09-30 | $11.24 Million | $-2.70 Million | -0.241x | +62.19% |
| 2012-09-30 | $1.64 Million | $-1.04 Million | -0.636x | -6798.55% |
| 2011-09-30 | $82.42 Million | $-760.31K | -0.009x | +98.96% |
| 2009-09-30 | $718.02K | $-636.48K | -0.886x | -- |
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more